Teacher Retirement System of Texas Sells 3,969 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Teacher Retirement System of Texas reduced its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPHFree Report) by 28.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,100 shares of the biopharmaceutical company’s stock after selling 3,969 shares during the quarter. Teacher Retirement System of Texas’ holdings in Theravance Biopharma were worth $114,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in Theravance Biopharma by 324.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 4,402 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Theravance Biopharma by 31.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 2,227 shares during the last quarter. Simplicity Solutions LLC purchased a new stake in Theravance Biopharma during the fourth quarter valued at $141,000. Bleakley Financial Group LLC purchased a new stake in Theravance Biopharma during the fourth quarter valued at $141,000. Finally, Principal Financial Group Inc. increased its position in Theravance Biopharma by 10.5% during the third quarter. Principal Financial Group Inc. now owns 18,637 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 1,764 shares during the last quarter. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Trading Up 2.4 %

NASDAQ:TBPH opened at $8.49 on Friday. Theravance Biopharma, Inc. has a 12-month low of $8.13 and a 12-month high of $11.71. The stock has a 50-day moving average price of $9.16 and a 200 day moving average price of $9.61. The stock has a market capitalization of $412.87 million, a P/E ratio of -9.87 and a beta of 0.36.

Theravance Biopharma (NASDAQ:TBPHGet Free Report) last released its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Theravance Biopharma had a negative return on equity of 18.97% and a negative net margin of 72.79%. The business had revenue of $17.57 million for the quarter, compared to analysts’ expectations of $17.49 million. On average, research analysts predict that Theravance Biopharma, Inc. will post -0.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on TBPH shares. StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Theravance Biopharma in a research report on Wednesday. Finally, BTIG Research began coverage on Theravance Biopharma in a research report on Friday, April 12th. They issued a “buy” rating and a $21.00 price target for the company.

Read Our Latest Stock Report on TBPH

Theravance Biopharma Profile

(Free Report)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Featured Stories

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPHFree Report).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.